Curaleaf Stock CURA · Forecast & Analysis
The picture for Curaleaf (CURA) is bullish on news strength, with no chart reading available because price history is too thin. The main reason is its bid for Aurora clearing competition hurdles in Germany and Canada, alongside record third-quarter revenue.
News situation · 8 items / 30 D
8 of 8 straight from the issuer or regulator
Outlook for Curaleaf Holdings
Direction, typical moves and upcoming dates from our own price, news and calendar data, recalculated on every visit. An assessment, not investment advice.
No price statement: there is no price data for this asset. Based on 8 news items.
What drives it
- The Aurora bid has secured German and Canadian competition clearances, cutting deal risk versus the competing Organigram proposal and…
- Third-quarter net revenue hit a record $353 million, with adjusted EBITDA of $78 million and a 49% adjusted gross margin supporting the…
- Expansion to four New Jersey dispensaries through the Boone Town Provisions deal broadens the retail footprint in a key US state.
- The offer's December 4 expiry suggests a potential near-term resolution to the takeover question.
What argues against it
- The Aurora offer still hinges on remaining conditions and on how Aurora's board responds, which is not yet settled.
- The enhanced premium bid raises the cost of the acquisition, tempering the benefit of lower deal risk.
- The results release gives no guidance or prior-period comparison, limiting how far the record quarter can re-rate the stock.
- Profitability is stated on an adjusted basis, not GAAP, so reported earnings may look different.
What would change the picture
- A refusal or further delay from Aurora's board, or unsatisfied offer conditions ahead of the December 4 expiry, would cool the…
- Fresh figures on US jobs, producer prices and retail sales land shortly; as backdrop alone, weak readings could weigh on sentiment…
Coming up
- US: Retail sales · expected 0.7%, previous 0.9%
- US: EIA Crude Oil Stocks Change · expected -0.309M, previous 4.657M
- US: Jobless claims, Philadelphia Fed Manufacturing Index · expected 32.2, previous 20.9
Economic data for CURA
Full calendarRecently released
- November 13, 2026USDCore PPI m/m●●●Actual 0.3%Forecast 0.4%Previous 0.8%
- November 13, 2026USDPPI m/m●●●Actual 0.3%Forecast 0.4%Previous 1.4%
Coming up
- TomorrowUSDCore Retail Sales m/m●●●Forecast 0.7%Previous 0.9%in 1 day
- TomorrowUSDRetail Sales m/m●●●Forecast 0.3%Previous 0.8%in 1 day
- November 18, 2026USDEIA Crude Oil Stocks Change●●●Forecast -0.309MPrevious 4.657Min 2 days
- November 19, 2026USDInitial Jobless Claims●●●in 3 days
- November 19, 2026USDPhiladelphia Fed Manufacturing Index●●●Forecast 32.2Previous 20.9in 3 days
- November 20, 2026USDMichigan Consumer Sentiment●●●Forecast 51.0Previous 51.0in 4 days
All times UTC. Assessed against the consensus forecast, otherwise against the previous value.
Both worlds over time
Technical and news signals of the last 30 days on one timeline.
What is being reported about CURA
Frequently asked questions about Curaleaf Holdings
What is the latest on Curaleaf's bid for Aurora Cannabis?
All required competition clearances are in hand: Germany's cartel office confirmed on November 3 and Canada's Competition Bureau issued a no-action letter on November 2. That leaves only remaining offer conditions and Aurora's board response before the offer expires on December 4, materially reducing deal risk versus the competing Organigram proposal.
How strong were Curaleaf's third-quarter results?
Net revenue reached a record $353 million, with $59 million from international operations, a 49% adjusted gross margin and adjusted EBITDA of $78 million. The release offers no guidance or comparison with prior periods, so it is hard to judge whether this beat expectations, and profitability is adjusted rather than GAAP.
What could change the bullish view on CURA?
The deal story is the pivot: if Aurora's board rejects the offer or conditions remain unsatisfied as the December 4 expiry approaches, the lower-risk closing argument weakens. Operationally, watch how quickly the New Jersey expansion and incubator graduates convert into revenue, since the record quarter lacked forward guidance to build on.
📝 Overview Generated automatically
CURA has been the subject of 13 signals across 13 articles in the last 365 days. Sentiment skews Bullish (54%).
Breakdown: 7 bullish, 0 bearish, 6 neutral.
Most-cited catalysts: TGA registration of the QMID device in Australia (1×), Official launch and availability of QMID in Australia and New Zealand markets (1×), Submission of an enhanced acquisition proposal to Aurora Cannabis (1×). Most-cited risk factors: Regulatory hurdles in international medical cannabis markets (1×), Dependence on partnership with Jupiter Research LLC for device supply (1×), Potential for continued board rejection from Aurora (1×).
Related assets
Same category or comparable signal picture — each card opens the full cockpit.